Clinical Trial Update: A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating SHR-1210 with or without SHR-1020 versus chemotherapy in recurrent or metastatic cervical cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• SHR-1020
• SHR-1210 (camrelizumab)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Recurrent or Metastatic Cervical Cancer | Phase 2 | Status: COMPLETED